Drugs / MRX34
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01829971 | Apr 2013 → Mar 2017 | liver cancer, melanoma, non-small cell lung carcinoma, plasma cell myeloma +2 | Mirna Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02862145 | Aug 2016 → Sep 2017 | melanoma | Mirna Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRX34 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02862145 ↗ |
| Known as | miR-RX34 | “A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection” NCT01829971 ↗ |
| Modality | Oligonucleotide (other) | “MicroRNA miR-Rx34 Liposomal Injection” NCT02862145 ↗ |
| Route | Intravenous | “The drug is given intravenously” NCT01829971 ↗ |